Burning Rock Biotech Limited (BNR) Earnings
Burning Rock Biotech Limited is expected to report next earnings on September 2, 2026 (in NaN days), with a consensus EPS estimate of $-2.31. BNR has beaten EPS estimates in 6 of its last 9 reported quarters (average surprise +67.3% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jun 9, 2026 | $-2.29 | $-0.20 | +91.3% | $16M | -18.3% |
| Nov 20, 2025 | — | $-0.26 | — | $18M | — |
| Sep 8, 2025 | — | $-0.15 | — | $21M | — |
| Jun 6, 2025 | — | $-0.17 | — | $18M | — |
| Mar 25, 2025 | $-1.40 | $-1.08 | +22.7% | $17M | — |
| Dec 3, 2024 | $-1.41 | $-0.50 | +64.5% | $18M | — |
| Aug 22, 2024 | $-1.49 | $-0.14 | +90.6% | $19M | — |
| May 29, 2024 | $-1.52 | $-0.16 | +89.5% | $17M | — |
| Nov 30, 2023 | $-1.81 | $-2.30 | -27.2% | $17M | -13.3% |
| Aug 31, 2023 | $-1.89 | $-1.80 | +4.7% | $20M | +0.3% |
| May 30, 2023 | $-2.00 | $-2.60 | -30.0% | $21M | +3.0% |
| Nov 15, 2022 | $-2.80 | $-3.10 | -10.7% | $22M | +0.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2024 · May 29, 2024
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Sales and marketing expenses as a percentage of revenue reached 35% in the latest quarter, a historic low, driving improved sales efficiency. - Gross profit margin continued to progress with no material update in the quarter. - General and admin expenses reduced through measures like headcount reduction and office space reduction. - R&D expenses were reduced. - Achieved positive non-GAAP gross profit minus G&A in Q1 2024, ahead of the original half-year guidance. - Cash position: Ended Q1 with RMB573 million cash balance. Cash outflow for 2024 is guided to be between RMB150 million and RMB200 million. Expect further savings in 2025 with a 3-year cash runway, eliminating immediate need for capital raising. - Transition from central lab to in-hospital accelerated, with Q1 2024 seeing in-hospital revenue surpass central lab revenue.
Guidance
- Cash outflow for 2024 is expected to be in the range of RMB150 million to RMB200 million. - Aim to achieve positive non-GAAP gross profit minus G&A for the entire year 2024. - Expect further cost savings in 2025, but no specific quantitative guidance provided at this stage. - Has a 3-year cash runway, so no immediate need for capital raising.
Segment performance
In Q1 2024, the clinical business saw revenue up 4% quarter-over-quarter. A key development was the transition from central lab to in-hospital, with Q1 marking the first quarter where in-hospital revenue exceeded central lab revenue.